Asia-Pacific viscosupplementation Market, By Source (Animal Origin And Non-Animal Origin), Age Group (Geriatric And Adults), Injection (Single Injection, Three Injections, And Five Injections), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight And High Molecular Weight), End User (Hospital, Orthopedic Clinics, Ambulatory Care Centers, And Others), Distribution Channel (Direct Tender And Retail Sales).
Asia-Pacific Viscosupplementation Market Analysis and Insights
Asia-Pacific viscosupplementation market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.6% in the forecast period of 2022 to 2029. Technological advancements in viscosupplementation treatments rise in the healthcare sector are another factor that drives the growth of the Asia-Pacific viscosupplementation market in the forecast period.
However, the high cost associated with the treatments and side effects such as temporary injection, site pain, swelling, heat, and redness loss will restrain the market's growth. Adoption of strategic alliances like partnerships and acquisitions by key market players act as an opportunity for the growth of the Asia-Pacific viscosupplementation market.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020
|
|
Quantitative Units
|
Revenue in USD Million Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Source (Animal Origin And Non-Animal Origin), Age Group (Geriatric And Adults), Injection (Single Injection, Three Injections, And Five Injections), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight And High Molecular Weight), End User (Hospital, Orthopedic Clinics, Ambulatory Care Centers, And Others), Distribution Channel (Direct Tender And Retail Sales)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Australia, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Some of the key players operating in the Asia-Pacific viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., L.G. Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), among others.
|
Market Definition
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Dynamics
Drivers
- Rising geriatric population
With this increasing age comes a reciprocal increase in the elderly patients admitted to the hospitals due to fatal traumatic injuries. The rising prevalence of knee osteoarthritis diseases increases the demand for diagnosis and treatment. With the growing population, the pressure on the healthcare system is rising. The increasing need for the proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as sarcopenia, osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. In such patients, viscosupplementation is used in the procedure to provide them with immediate and efficient benefits associated with their bodies.
With this increasing age and rising prevalence of osteoarthritis, the demand for early diagnosis of the diseases is also increasing. Therefore, the need for viscosupplementation is rising for the treatment in the healthcare system across the globe.
- Increasing risk of osteoporosis and osteoarthritis
Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease is silent and typically shows no symptoms. Mostly older people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.
The silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone, among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the Asia-Pacific viscosupplementation market.
Restraint
- Lack of technical expertise
Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but this number is much less across the globe as these procedures are complex.
However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.
Thus, the lack of technical expertise may act as a restraint for the market's growth.
Opportunity
-
Safety and effectiveness of intra-articular hyaluronic acid (IAHA)
There are several types of hyaluronic acid injections, also called viscosupplementation, which are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a U.S. Food and Drug Administration-approved treatment for knee osteoarthritis (O.A.). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic A.E.s associated with I.A. corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.
Challenge
- Stringent government policies for THE USE OF viscosupplementation
The commercialization of viscosupplementation across the globe by various key market players is facilitated by compliance with the regulatory frameworks established by many countries across the globe. The pre-market approval of various medical devices varies from one country to another. The U.S. Food, Drug, and Cosmetic Act ("FD&C Act") classify medical devices in the U.S. The European Union (E.U.) regulates medical devices in Europe. However, the rapid development of privacy policies and regulations are being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia.
The viscosupplementation is regulated by a structure of laws, rules, and regulations that are extensive and complex to safeguard them from use in any potential harmful treatment.
The viscosupplementation act as a replacement for the damaged, injured, or infected body parts in cases of osteoarthritis conditions or sports accidents among patients, along with maintaining the patient's demand for good body movement. However, any misguidance will affect the patient's safety and body structure.
Therefore, the stringent rules & regulations for the use of viscosupplementation may act as a challenge to the growth of the market.
Post COVID-19 Impact on Asia-Pacific Viscosupplementation Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the Asia-Pacific viscosupplementation market.
Asia-Pacific Viscosupplementation Market Scope and Market Size
Asia-Pacific viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.
BY SOURCE
- ANIMAL ORIGIN
- NON-ANIMAL ORIGIN
On the basis of source, the viscosupplementation market is segmented into the animal origin and non-animal origin.
BY MOLECULAR WEIGHT
- HIGH MOLECULAR WEIGHT
- LOW MOLECULAR WEIGHT
- INTERMEDIATE MOLECULAR WEIGHT
On the basis of molecular weight, the viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.
BY INJECTION
- SINGLE INJECTION
- THREE INJECTION
- FIVE INJECTION
On the basis of injection, the viscosupplementation market is segmented into single injection, three injections, and five injections.
BY AGE GROUP
- ADULTS
- GERIATRICS
On the basis of age group, the viscosupplementation market is segmented into geriatric and adults.
END-USER
- HOSPITALS
- ORTHOPEDIC CLINIC
- HOME HEALTHCARE
- OTHERS
On the basis of end-user, the viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others.
BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
On the basis of distribution channel, the viscosupplementation market is segmented into direct tender and retail sales.
Viscosupplementation Market Country Level Analysis
The viscosupplementation market is analyzed, and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.
The countries covered in the viscosupplementation market report are the China, Japan, India, South Korea, Singapore, Australia, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific.
In 2022, China is dominating due to the increasing demand for non-surgical treatments for osteoarthritis with high GDP. China is expected to grow due to the rise in technological advancement in drug treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.
Viscosupplementation market also provides you with a detailed market analysis of every country growth in the healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, the impact of regulatory scenarios, and trending parameters regarding the viscosupplementation market.
Competitive Landscape and Asia-Pacific Viscosupplementation Market Share Analysis
Viscosupplementation market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to viscosupplementation treatments.
The major companies which are dealing in the viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., L.G. Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), among others
Strategic alliances like mergers, acquisitions, and agreements by the key market players are further expected to accelerate the growth of viscosupplementation treatments.
For instance,
- In May 2022, Fidia Farmaceutici S.p.A. harnesses the regenerative power of hyaluronic acid with its innovative portfolio launched in Spain
Fidia Farmaceutici S.p.A. presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. The company has launched its complete Hyal System and Hy-Tissue portfolio in Spain. This has helped the company to showcase its research for hyaluronic acid
- In June 2022, Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis,b spinal pain, and disease severityc endpoints – irrespective of baseline characteristics. This has helped the company to showcase its progress
- In November 2021, L.G. Chem initiated clinical development for the development of new next-generation osteoarthritis treatment. L.G. Chem announced that the Company had received approval from the Korean Ministry of Food and Drug Safety for the Phase 1b/2 clinical trials based on the positive pre-clinical results of LG00034053, a new drug candidate for the treatment of osteoarthritis. L.G. Chem plans to accelerate the development of new drugs by designing clinical trials which link Phases 1 and 2
This has helped the company go for new drugs to treat osteoarthritis.
- In November 2020, Viatris Inc. launched a successful combination of Mylan N.V. and Pfizer's Upjohn business. By combining these two complementary legacy companies, Viatris has the scientific, manufacturing, and distribution expertise with proven regulatory, medical, and Asia-Pacific commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. This has helped the company to expand its business
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the Asia-Pacific viscosupplementation market, which also benefits the organization’s profit growth.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-